The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

curocellbtx.com

Founded Year

2017

Stage

Series D | Alive

Total Raised

$82.85M

Last Raised

$30.13M | 5 mos ago

About Curocell

Curocell is a Korea-based biotechnology company that discovers and develops CAR-T therapies for various solid cancers, including blood cancer.

Curocell Headquarter Location

KHE Building 3F 48, Yuseong-daero 1184beon-gil, Yuseong-gu

Daejeon, 34109,

South Korea

+82-42-863-3698

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Curocell

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Curocell is included in 3 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Curocell Patents

Curocell has filed 2 patents.

The 3 most popular patent topics include:

  • Cancer treatments
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/18/2021

Clusters of differentiation, Immunology, Immune system, Transcription factors, Cancer treatments

Application

Application Date

3/18/2021

Grant Date

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Transcription factors, Cancer treatments

Status

Application

Latest Curocell News

SK Plasma to reorganize blood product-centered biz portfolio

Jan 13, 2022

SK Plasma to reorganize blood product-centered biz portfolio 바로가기 기자명 Lee Han-soo 닫기 SK Plasma said Thursday that it would shed its image as a company specializing only in blood products to expand and reorganize its business portfolio into rare, incurable diseases. SK Plasma said it has picked rare, incurable disease treatments as its new growth engine. The company will officially kick off an investment project for rare, incurable diseases with Tium Bio and Korea Investment Partners armed with the additional capital of 110 billion won ($92.5 million) made by receiving investment from SK Discovery and the two partners last year. To this end, the company has operated an NRDO (No Research Development Only) unit to secure a new drug pipeline in the field of rare, incurable diseases. Immediately after attracting the investment, SK Plasma established an organization dedicated to promoting NRDO and an R&D committee, attracting strategic investors, and reviewing new drug candidates for rare, incurable diseases under development by Korean and foreign bio ventures, according to the company. For instance, SK Plasma selected Curocell's CAR-T (chimeric antigen receptor T cell) as its first NRDO project and recently participated in Curocell's pre-initial public offering (IPO) as a strategic investor. It also decided to jointly promote global commercialization of CAR-T treatment as a strategic investor in the future. "The CAR-T treatment under development by Curocell is an innovative new drug that enables the recovery and cure of cancer patients who cannot receive treatment with existing technologies," an SK Plasma official said. "Through close collaboration with Curocell, we will promote the successful development and commercialization of CAR-T therapeutics to foster CAR-T therapeutics as SK Plasma's core biopharmaceutical pipeline in the future." Besides, SK Plasma plans to discover new drug candidates by quickly and closely reviewing them with the NRDO organization as the center and gradually increasing its pipeline for treating rare, incurable diseases through close cooperation with partner companies. "Rare and incurable diseases is a significant field as it can relieve the sufferings of many patients who have to endure lifelong pain because there is no treatment, regardless of economic value," SK Plasma CEO Kim Yun-ho said. "We plan to be reborn as a pharmaceutical company specializing in rare and incurable diseases by continuously discovering new drug candidates through NRDO-centered R&D strategies." According to BCC Research, a drug market research firm, the global rare and incurable disease treatment market stood at $190.8 billion last year but will grow to $248.2 billion by 2026, recording an annual growth rate of 5.4 percent.

Curocell Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Curocell Rank

  • When was Curocell founded?

    Curocell was founded in 2017.

  • Where is Curocell's headquarters?

    Curocell's headquarters is located at KHE Building 3F, Daejeon.

  • What is Curocell's latest funding round?

    Curocell's latest funding round is Series D.

  • How much did Curocell raise?

    Curocell raised a total of $82.85M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.